<DOC>
	<DOCNO>NCT01008774</DOCNO>
	<brief_summary>Primary objective : - Rate complete chemotherapy induce alopecia ( WHO grade III IV , physician grading ) Secondary objective : - Compliance scalp cool procedure - Received number cycle chemotherapy subgroup - Patient perception scalp cool procedure - Side effect scalp cool system</brief_summary>
	<brief_title>START : Swiss Taxotere Alopecia Prevention Trial</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<criteria>Any solid tumor malignancy receive docetaxel ( TaxotereÂ® ) 1st line chemotherapy treatment exception regimen contain concomitant anthracycline treatment ; sequential anthracycline/docetaxel treatment permit . Performance Status ECOG &lt; = 2 Absence alopecia inclusion Chemotherapy regimen include concomitant anthracycline treatment Raynaud 's disease phenomenon Cold agglutinin disease Cryoglobulinemia Cryofibrinogenemia Scalp metastasis Pregnancy Lactation Preexisting alopecia grade ; notably androgenetic alopecia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>